CEL-SCI Corporation

CEL-SCI Corporation is involved in the research and development of certain drugs and vaccines. CEL-SCI's first product, MULTIKINE(TM), manufactured using the Company's proprietary cell culture technologies, is a combination, or "cocktail", of natural human interleukin-2 ("IL-2") and certain lymphokines and cytokines. MULTIKINE is being tested to determine if it is effective in improving the immune response of cancer patients. CEL-SCI's second product, HGP-30, is being tested to determine if it is an effective vaccine/treatment against the AIDS virus. The third technology CEL-SCI is developing, LEAPS (Ligand Epitope Antigen Presentation System) is a T-cell modulation technology which can be used to direct a specific immune response and which is thought to be particularly important in the case of diseases which have no approved vaccinations (e.g. herpes simplex, malaria, AIDS, etc.) The Company intends to use this new technology to improve the cellular immune response of persons vaccinated with HGP-30 and to develop potential treatments and/or vaccines against various diseases. Present target diseases are AIDS, herpes simplex, malaria, tuberculosis, prostate cancer and breast cancer.

Contact Details: 8229 Boone Boulevard, Suite 802 Vienna VA 22182 United States of America Tel: 703 506-9460 Fax: (703) 506-9471 Email:

Loading...

Recent Publications by CEL-SCI Corporation:
The L.E.A.P.S. approach to vaccine development. The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to...	11th July, 2006	Cel-Sci Corporation, 8229 Boone Blvd, Suite 802, Vienna, VA 22182, USA.	Front Biosci. 2005 Jan 1;10:790-8. Print 2005 Jan 1.
A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. CEL-1000 (DGQEEKAGVVSTGLIGGG) is a novel potential preventative and...	8th September, 2004	CEL-SCI Corporation, 8229 Boone Blvd., Suite 802, Vienna, VA 22182, USA.	Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63. DOI Direct Link

Press Releases on CEL-SCI Corporation:
CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine	18th November, 2009	CEL-SCI Corporation	VIENNA, Va., Nov. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response	9th November, 2009	CEL-SCI Corporation	VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine	6th November, 2009	CEL-SCI Corporation	VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology
CEL-SCI Corporation Strengthens Balance Sheet Through Receipt of $10 Million From Warrant Exercises	26th October, 2009	CEL-SCI Corporation	VIENNA, Va., Oct. 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by
CEL-SCI Presents Data at American College of Rheumatology Conference Which Suggests that CEL-2000 Has Potential to Slow Damage Caused by Rheumatoid Arthritis	19th October, 2009	CEL-SCI Corporation	VIENNA, Va., Oct. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today the presentation of new rheumatoid arthritis data at the American College of Rheumatology's

BioNews Results for CEL-SCI Corporation:
Is Amendment of Previously Filed Paperwork a Sign That CEL-SCI is Expecting Something Big?	Genetic Engineering News:  Nov 12 2009 2:39PM Matching: cel sci
Is Amendment of Previously Filed Paperwork a Sign That CEL-SCI is Expecting Something Big?	Freshnews.com:  Nov 12 2009 1:30PM Matching: cel sci
Is Amendment of Previously Filed Paperwork a Sign That CEL-SCI is Expecting Something Big?	Individual.com:  Nov 12 2009 7:01PM Matching: cel sci
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response	Pharma Live:  Nov 10 2009 9:38PM Matching: cel sci
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response	KOTA Territory News:  Nov 10 2009 11:59AM Matching: cel sci
Promote your company here: BioNewsCast - Press Release Distribution	→View more CEL-SCI Corporation news.

CEL-SCI Corporation Patents:
US Patent No.	Title
7256254	Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
7199216	Peptide constructs for treating autoimmune and related diseases
6995237	Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
6951647	T cell binding ligand peptides and method of inducing a cellular immune response
6896879	Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
→View more CEL-SCI Corporation patents.

CEL-SCI Corporation (CVM) Financial information Links from Barchart
CVM Quote from from Barchart.com
CVM Chart from from Barchart.com
CVM Profile from from Barchart.com
CVM Opinion from from Barchart.com
→View more CEL-SCI Corporation finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 394 times since April 2007, the link to the organisation's website has been followed 0 times

Search for more companies in Vienna

Search for more companies in VA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for CEL-SCI Corporation